To include your compound in the COVID-19 Resource Center, submit it here.

Breo Ellipta: Phase III data

The double-blind, international Phase III SUMMIT trial in 16,485 COPD patients with moderate airflow limitation (50-70% predicted FEV1) and a history or risk of cardiovascular disease showed that once-daily 100/25 ug Breo Ellipta missed the primary endpoint of reducing

Read the full 391 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers